title: The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma.
abstract: OBJECTIVE
  To determine the outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma.
  
  
  METHODS
  Prospective analysis of 27 eyes in 22 patients with group V retinoblastoma treated with either 2- or 6-cycle chemoreduction and focal treatment methods (argon laser photocoagulation, transpupillary thermotherapy, cryotherapy, and plaque radiotherapy). The need for external beam irradiation and the eventual globe salvage rate were assessed. Median follow-up was 28 months.
  
  
  RESULTS
  There were 16 eyes in the 2-cycle chemoreduction treatment group and 11 eyes in the 6-cycle chemoreduction treatment group. No significant difference was noted between the 2 groups with respect to baseline patient and eye findings. After chemoreduction treatment, external beam irradiation was necessary in 12 (75%) of 16 eyes in the 2-cycle chemoreduction treatment group and in 4 (36%) of 11 eyes in the 6-cycle chemoreduction treatment group. There was no statistical difference between the 2- and 6-cycle chemoreduction treatment groups with respect to necessity for external beam irradiation (logistic regression analysis). All 4 eyes in the 2-cycle chemoreduction treatment group and 3 of 12 eyes in the 2-cycle chemoreduction treatment and irradiation group were eventually enucleated, the globe salvage rates being 0% and 75%, respectively. Two of 7 eyes in the 6-cycle chemoreduction treatment group and 1 of 4 eyes in the 6-cycle chemoreduction treatment and irradiation group were enucleated, the globe salvage rates being 71% and 75%, respectively. Except for the 2-cycle chemoreduction treatment group, in which the globe salvage rate was significantly lower (P = .03), there was no difference among the other 3 groups (2-cycle chemoreduction treatment and irradiation, 6-cycle chemoreduction treatment, and 6-cycle chemoreduction treatment and irradiation) with respect to globe salvage (logistic regression analysis).
  
  
  CONCLUSIONS
  Local tumor control of group V retinoblastoma is possible with 6-cycle chemoreduction and focal therapy when external beam irradiation is not used. A larger sample size is necessary to determine how often external beam irradiation can be avoided.
authors.affiliation: Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pa., USA.
authors.forename: K
authors.initials: K
authors.lastname: Gündüz
authors.forename: C L
authors.initials: CL
authors.lastname: Shields
authors.forename: J A
authors.initials: JA
authors.lastname: Shields
authors.forename: A T
authors.initials: AT
authors.lastname: Meadows
authors.forename: N
authors.initials: N
authors.lastname: Gross
authors.forename: J
authors.initials: J
authors.lastname: Cater
authors.forename: M
authors.initials: M
authors.lastname: Needle
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001918:Brachytherapy; D016190:Carboplatin / Q000008:administration & dosage; D002675:Child, Preschool; D003452:Cryosurgery; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D015353:Eye Enucleation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006979:Hyperthermia, Induced; D007223:Infant; D017075:Laser Coagulation; D008297:Male; D011446:Prospective Studies; D019572:Retinal Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D012175:Retinoblastoma / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D016190:Carboplatin